Latest Alliqua Inc (ALQA) Headlines $ALQA
EquitiesIQ Interviews David Johnson, CEO of Alliqua
ACCESSWIRE - Wed Mar 19, 12:30PM CDT
Watch the Interview: http://equitiesiq.com/alliqua-interview/
Alliqua to Present at 26th Annual ROTH Conference on March 10
GlobeNewswire - Mon Mar 03, 6:01AM CST
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company") announces that David Johnson, Chief Executive Officer, will present at the 26th Annual ROTH Conference at The Ritz-Carlton in Laguna Niguel, CA. Mr. Johnson is scheduled to present on Monday, March 10 at 2:00 pm PT (5:00 pm ET) in Track 6, Salon 6.
Alliqua, Inc. [ALQA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Feb 21, 9:00AM CST
What:
Alliqua, Inc. Profiled by TheStreet.com and Philadelphia Business Journal
Business Wire - Thu Feb 13, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or the "Company") was featured in a video interview published by TheStreet.com and in an article published by the Philadelphia Business Journal.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into ALLIQUA, INC. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Tue Feb 11, 11:01AM CST
Levi & Korsinsky, LLP is investigating Alliqua, Inc. (NasdaqCM: ALQA) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Alliqua names Janice M Smiell as company's first chief medical officer
M2 - Tue Feb 11, 7:29AM CST
US-based wound care and drug delivery specialists Alliqua Inc (Nasdaq:ALQA) announced on Monday the appointment of Janice M Smiell MD to the newly created position of chief medical officer.
SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics
PR Newswire - Tue Feb 11, 7:00AM CST
SeraCare Life Sciences, a provider of high quality biological materials and reagents that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding member of the SeraCare Science Advisory Board. This group will bring together thought leaders in emerging technologies and applications such as NexGen sequencing, clinical oncology and autoimmune disease to foster collaboration and innovation.
Alliqua Appoints Janice M. Smiell, M.D. as its First Chief Medical Officer
Business Wire - Mon Feb 10, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company") has appointed Janice M. Smiell, M.D. as its Chief Medical Officer, a newly created position.
Alliqua's CEO Issues Letter to Shareholders
Business Wire - Mon Feb 03, 6:30AM CST
David Johnson, CEO of Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), has issued the following letter to shareholders:
10-Q: MISTRAS GROUP, INC.
Edgar Online - Thu Jan 09, 3:07PM CST
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Alliqua Appoints Perry A. Karsen to Board of Directors
PR Newswire - Wed Dec 04, 7:00AM CST
CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to Alliqua's Board
Alliqua Announces Transaction with Celgene
Business Wire - Tue Nov 19, 6:30AM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") entered into a licensing agreement with Celgene Cellular Therapeutics ("CCT"), a subsidiary of Celgene Corporation (NASDAQ:CELG) ("Celgene"), whereby Alliqua received the right to develop and market the advanced wound care products Biovance(R) and Extracellular Matrix (ECM). Concurrently with the license agreement, Alliqua entered into an agreement with Celgene to sell to Celgene 1,672,474 shares of common stock of Alliqua, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In connection with this agreement to invest in Alliqua's securities, Celgene received a right to appoint a director to Alliqua's Board of Directors. Concurrent to this transaction, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested an additional $7 million on comparable financial terms. Alere Financial Partners, a division of Summer Street Research Partners, acted as placement agent for the transaction with these investors.
Alliqua Announces Reverse Split of Common Stock
Business Wire - Mon Nov 18, 4:02PM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or "the Company") announced it effected a one (1) for 43.75 reverse split of its common stock (the "Reverse Split") as a step toward the Company's intention to have its common stock listed on a national exchange.
Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Alliqua Receives $1M from Crossover Healthcare Fund, LLC to Pursue Key Wound Care Initiatives
PR Newswire - Tue Nov 12, 6:30AM CST
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), obtained $1 million in financing from Crossover Healthcare Fund, LLC, with the financing to be used to pursue the Company's key initiatives in the wound care space.
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer
PR Newswire - Mon Oct 21, 8:05AM CDT
Market news updates for October Biotech leaders: Alliqua Inc. (OTCQB: ALQA), MiMedx Group, Inc. (NASDAQ: MDXG), Organovo Holdings, Inc. (NYSE: ONVO) Anacor Pharmaceuticals (NASDAQ: ANAC) and Pfizer Inc. (NYSE: PFE)
Alliqua Signs Distribution Agreement for SilverSeal® and Hydress® Wound Dressings
PR Newswire - Mon Oct 21, 7:00AM CDT
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), has signed a distribution agreement with McKesson Medical-Surgical, by which their U.S. distribution network will stock and offer for sale Alliqua's SilverSeal® and Hydress® wound dressings to healthcare customers nationwide.
Preclinical Results Show Alliqua's Investigational Lidocaine Transdermal Patch Compares Favorably to Lidoderm Patch
PR Newswire - Wed Oct 16, 7:00AM CDT
A preclinical study commissioned by Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm® (Lidocaine patch 5%) patch that is currently on the market. The overall study results indicate that Alliqua's patch is able to deliver in the pig a slightly higher amount of lidocaine than Lidoderm and to reach maximum delivery within a comparable period. No skin irritation occurred with either the Alliqua transdermal patch or Lidoderm patch. The study concludes that further development could result in Alliqua creating a commercial lidocaine patch that could be a generic version of the Lidoderm patch or provide better drug delivery resulting in a 505 (b)(2) approval.
Alliqua Provides Update on Media Coverage of its Advanced Wound Care Portfolio and Corporate Developments
PR Newswire - Mon Oct 07, 7:00AM CDT
Alliqua, Inc. provided an update on a series of independent news stories highlighting the Company's wound care portfolio and corporate developments. The links below provide direct access to each complete article.
Alliqua Appoints Brian M. Posner as Chief Financial Officer
Marketwire - Tue Sep 03, 7:02AM CDT
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), a biomedical company offering a suite of wound care solutions and drug delivery technologies, has appointed Brian M. Posner as Chief Financial Officer, effective immediately. The appointment coincides with the Company's official relocation of its headquarters to Langhorne, Pennsylvania. Steve Berger, Alliqua's current CFO, will remain with the Company through the end of 2013 to help ensure a smooth transition.
EquitiesIQ Interviews David Johnson, CEO of Alliqua
ACCESSWIRE - Wed Mar 19, 12:30PM CDT
Watch the Interview: http://equitiesiq.com/alliqua-interview/
Alliqua to Present at 26th Annual ROTH Conference on March 10
GlobeNewswire - Mon Mar 03, 6:01AM CST
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company") announces that David Johnson, Chief Executive Officer, will present at the 26th Annual ROTH Conference at The Ritz-Carlton in Laguna Niguel, CA. Mr. Johnson is scheduled to present on Monday, March 10 at 2:00 pm PT (5:00 pm ET) in Track 6, Salon 6.
Alliqua, Inc. [ALQA] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Feb 21, 9:00AM CST
What:
Alliqua, Inc. Profiled by TheStreet.com and Philadelphia Business Journal
Business Wire - Thu Feb 13, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or the "Company") was featured in a video interview published by TheStreet.com and in an article published by the Philadelphia Business Journal.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into ALLIQUA, INC. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Tue Feb 11, 11:01AM CST
Levi & Korsinsky, LLP is investigating Alliqua, Inc. (NasdaqCM: ALQA) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Alliqua names Janice M Smiell as company's first chief medical officer
M2 - Tue Feb 11, 7:29AM CST
US-based wound care and drug delivery specialists Alliqua Inc (Nasdaq:ALQA) announced on Monday the appointment of Janice M Smiell MD to the newly created position of chief medical officer.
SeraCare Life Sciences and Dr. Jack Wands Spark Advancements in Oncology Diagnostics
PR Newswire - Tue Feb 11, 7:00AM CST
SeraCare Life Sciences, a provider of high quality biological materials and reagents that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today introduced Dr. Jack Wands as the founding member of the SeraCare Science Advisory Board. This group will bring together thought leaders in emerging technologies and applications such as NexGen sequencing, clinical oncology and autoimmune disease to foster collaboration and innovation.
Alliqua Appoints Janice M. Smiell, M.D. as its First Chief Medical Officer
Business Wire - Mon Feb 10, 6:00AM CST
Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company") has appointed Janice M. Smiell, M.D. as its Chief Medical Officer, a newly created position.
Alliqua's CEO Issues Letter to Shareholders
Business Wire - Mon Feb 03, 6:30AM CST
David Johnson, CEO of Alliqua, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), has issued the following letter to shareholders:
10-Q: MISTRAS GROUP, INC.
Edgar Online - Thu Jan 09, 3:07PM CST
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Alliqua Appoints Perry A. Karsen to Board of Directors
PR Newswire - Wed Dec 04, 7:00AM CST
CEO of Celgene Cellular Therapeutics To Add Further Depth and Value to Alliqua's Board
Alliqua Announces Transaction with Celgene
Business Wire - Tue Nov 19, 6:30AM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") entered into a licensing agreement with Celgene Cellular Therapeutics ("CCT"), a subsidiary of Celgene Corporation (NASDAQ:CELG) ("Celgene"), whereby Alliqua received the right to develop and market the advanced wound care products Biovance(R) and Extracellular Matrix (ECM). Concurrently with the license agreement, Alliqua entered into an agreement with Celgene to sell to Celgene 1,672,474 shares of common stock of Alliqua, at a purchase price of $3.59 per share and a five year warrant to purchase an additional 836,237 shares of common stock at an exercise price of $5.69, in exchange for $6.0 million. In connection with this agreement to invest in Alliqua's securities, Celgene received a right to appoint a director to Alliqua's Board of Directors. Concurrent to this transaction, several unrelated funds led by Broadfin Capital LLC and Perceptive Advisors LLC, invested an additional $7 million on comparable financial terms. Alere Financial Partners, a division of Summer Street Research Partners, acted as placement agent for the transaction with these investors.
Alliqua Announces Reverse Split of Common Stock
Business Wire - Mon Nov 18, 4:02PM CST
Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or "the Company") announced it effected a one (1) for 43.75 reverse split of its common stock (the "Reverse Split") as a step toward the Company's intention to have its common stock listed on a national exchange.
Navidea Biopharmaceuticals Adds New Member to Board of Directors
Business Wire - Fri Nov 15, 11:48AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of Directors.
Alliqua Receives $1M from Crossover Healthcare Fund, LLC to Pursue Key Wound Care Initiatives
PR Newswire - Tue Nov 12, 6:30AM CST
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), obtained $1 million in financing from Crossover Healthcare Fund, LLC, with the financing to be used to pursue the Company's key initiatives in the wound care space.
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer
PR Newswire - Mon Oct 21, 8:05AM CDT
Market news updates for October Biotech leaders: Alliqua Inc. (OTCQB: ALQA), MiMedx Group, Inc. (NASDAQ: MDXG), Organovo Holdings, Inc. (NYSE: ONVO) Anacor Pharmaceuticals (NASDAQ: ANAC) and Pfizer Inc. (NYSE: PFE)
Alliqua Signs Distribution Agreement for SilverSeal® and Hydress® Wound Dressings
PR Newswire - Mon Oct 21, 7:00AM CDT
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), has signed a distribution agreement with McKesson Medical-Surgical, by which their U.S. distribution network will stock and offer for sale Alliqua's SilverSeal® and Hydress® wound dressings to healthcare customers nationwide.
Preclinical Results Show Alliqua's Investigational Lidocaine Transdermal Patch Compares Favorably to Lidoderm Patch
PR Newswire - Wed Oct 16, 7:00AM CDT
A preclinical study commissioned by Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm® (Lidocaine patch 5%) patch that is currently on the market. The overall study results indicate that Alliqua's patch is able to deliver in the pig a slightly higher amount of lidocaine than Lidoderm and to reach maximum delivery within a comparable period. No skin irritation occurred with either the Alliqua transdermal patch or Lidoderm patch. The study concludes that further development could result in Alliqua creating a commercial lidocaine patch that could be a generic version of the Lidoderm patch or provide better drug delivery resulting in a 505 (b)(2) approval.
Alliqua Provides Update on Media Coverage of its Advanced Wound Care Portfolio and Corporate Developments
PR Newswire - Mon Oct 07, 7:00AM CDT
Alliqua, Inc. provided an update on a series of independent news stories highlighting the Company's wound care portfolio and corporate developments. The links below provide direct access to each complete article.
Alliqua Appoints Brian M. Posner as Chief Financial Officer
Marketwire - Tue Sep 03, 7:02AM CDT
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), a biomedical company offering a suite of wound care solutions and drug delivery technologies, has appointed Brian M. Posner as Chief Financial Officer, effective immediately. The appointment coincides with the Company's official relocation of its headquarters to Langhorne, Pennsylvania. Steve Berger, Alliqua's current CFO, will remain with the Company through the end of 2013 to help ensure a smooth transition.
